Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:18 pm Purchase | 2025-09-30 | 13G | Prime Medicine, Inc. PRME | T. Rowe Price Investment Management, Inc. | 9,236,955 5.300% | 9,236,955 (New Position) | Filing History |
| 2025-11-12 4:30 pm Purchase | 2025-09-30 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 16,562,498 12.300% | 1,500,000 (+9.96%) | Filing History |
| 2025-11-05 11:44 am Sale | 2025-09-30 | 13G | Prime Medicine, Inc. PRME | FMR LLC | 6,731,796 3.800% | -994,853 (-12.88%) | Filing History |
| 2025-08-11 9:48 pm Purchase | 2025-08-07 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 18,587,036 10.400% | 3,075,300 (+19.83%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Prime Medicine, Inc. PRME | Newpath Partners, L.P. | 6,105,679 4.700% | 800,000 (+15.08%) | Filing History |
| 2024-11-22 5:32 pm Purchase | 2024-11-12 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 15,511,736 11.800% | 39,062 (+0.25%) | Filing History |
| 2024-11-12 10:34 am Sale | 2024-11-08 | 13G | Prime Medicine, Inc. PRME | FMR LLC | 7,726,649 6.437% | -1,361,501 (-14.98%) | Filing History |
| 2024-10-04 4:20 pm Purchase | 2023-09-30 | 13G | Prime Medicine, Inc. PRME | BRISTOL MYERS SQUIBB CO BMY | 11,006,163 8.400% | 11,006,163 (New Position) | Filing History |
| 2024-02-29 4:15 pm Purchase | 2024-02-20 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 15,062,498 12.200% | 3,200,000 (+26.98%) | Filing History |
| 2024-02-22 9:31 pm Purchase | 2024-02-15 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 15,472,674 12.900% | 15,472,674 (New Position) | Filing History |
| 2024-02-09 4:09 pm Sale | 2023-12-31 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 11,862,498 12.200% | -1,422,190 (-10.71%) | Filing History |
| 2024-02-09 09:49 am Purchase | 2024-02-08 | 13G | Prime Medicine, Inc. PRME | FMR LLC | 9,088,150 9.338% | 625,104 (+7.39%) | Filing History |
| 2023-02-13 4:08 pm Purchase | 2022-12-31 | 13G | Prime Medicine, Inc. PRME | ARCH Venture Fund X L.P. | 12,272,674 12.600% | 12,272,674 (New Position) | Filing History |
| 2023-02-10 4:05 pm Purchase | 2022-12-31 | 13G | Prime Medicine, Inc. PRME | GV 2019, L.P. | 13,284,688 13.700% | 13,284,688 (New Position) | Filing History |
| 2023-02-09 08:14 am Purchase | 2023-02-09 | 13G | Prime Medicine, Inc. PRME | FMR LLC | 8,463,046 8.706% | 100 (+0.00%) | Filing History |
| 2023-02-07 4:46 pm Purchase | 2022-12-31 | 13G | Prime Medicine, Inc. PRME | Newpath Partners, L.P. | 5,305,679 5.500% | 5,305,679 (New Position) | Filing History |
| 2022-10-26 10:20 am Purchase | 2022-10-26 | 13G | Prime Medicine, Inc. PRME | FMR LLC | 8,462,946 8.840% | 8,462,946 (New Position) | Filing History |